Good morning, everyone, and how are you today? We are doing just fine, thank you, despite an unusually busy start to the new year. To cope, naturally we are firing up the coffee kettle to brew multiple cups of stimulation. Our choice today is peppermint mocha, since it offers a little zing. Meanwhile, we have assembled the usual menu of tidbits to help you get started yourselves. Hope today is as productive as possible and you conquer the world. And, as always, do keep in touch …

In a blockbuster deal, Bristol-Myers Squibb (BMY) plans to buy Celgene (CELG) for $74 billion, joining two of the largest players in oncology at a time when both have faced setbacks, STAT writes. Bristol-Myers pioneered the use of cancer medicines that work by priming the immune system, but its flagship blockbuster drug, Opdivo, has been surpassed by a rival medicine from Merck, especially in the market for lung cancer. Celgene, meanwhile, has faced a string of clinical and regulatory disappointments over the past year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy